EUVIMEDEUVIMED entdecken
Open Access

The Promise and Perils of Diversity Action Plans for Clinical Trials

Tanvee Varma, Barbara E Bierer, Andrew Hantel

JAMA · 03.12.2024 · 332 (21) · 1787

DOI: 10.1001/jama.2024.18225 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA, erschienen am 03.12.2024. Verfasst von Tanvee Varma und 2 weiteren Autor:innen. Beteiligte Einrichtung: Brigham and Women's Hospital, Boston, Massachusetts. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This Viewpoint discusses the US Food and Drug Administration’s authority to require drug and device sponsors to submit diversity action plans and policy gaps that limit the organization’s ability to achieve demographic representation in clinical trials.

Autor:innen und Institutionen

  • Brigham and Women's Hospital, Boston, Massachusetts.
  • Harvard Medical School, Boston, Massachusetts.
  • Dana-Farber Cancer Institute, Boston, Massachusetts.

Förderung

  • NCI NIH HHS

Zitieren

APA

Varma, T., Bierer, B. E., & Hantel, A. (2024). The Promise and Perils of Diversity Action Plans for Clinical Trials. JAMA, 332(21), 1787. https://doi.org/10.1001/jama.2024.18225

Vancouver

Varma T, Bierer BE, Hantel A. The Promise and Perils of Diversity Action Plans for Clinical Trials. JAMA. 2024;332(21):1787. doi:10.1001/jama.2024.18225

BibTeX
@article{Varma2024,
  author = {Varma, Tanvee and Bierer, Barbara E and Hantel, Andrew},
  title = {The Promise and Perils of Diversity Action Plans for Clinical Trials},
  journal = {JAMA},
  year = {2024},
  volume = {332},
  number = {21},
  pages = {1787},
  doi = {10.1001/jama.2024.18225}
}
Kostenlos starten →